From Wall Street Journal:

Novartis has withdrawn its pursuit of Cytokinetics, affecting the potential deal for the heart-drug developer. The Swiss drug giant was close to a purchase of Cytokinetics, expected to be finalized this week, according to The Wall Street Journal. However, Novartis, which had been pursuing the biotech for months, stepped back in the past day or two. This decision has dimmed the outlook for the potential acquisition. The copyright for the article belongs to Dow Jones & Company, Inc.



Read more: Novartis Pursuit of Cytokinetics Cools